Companies280Bio

280Bio

active
ZZ, China
Website
About

KRAS Inhibitor

Areas of Focus

Categories

Small Molecule PharmaceuticalChina
Clinical Trials (1)
View all

Total Trials

1

As Lead Sponsor

0

As Collaborator

1

Total Enrollment

4

By Phase

PHASE1: 1

By Status

TERMINATED: 1
Clinical Trials Pipeline1 trial
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2023
2024
2025
2026
Today
NCT06199466
Hover over trial bars to see details

Recent Trials

NCT06199466Collaborator
A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
PHASE1Terminated
4 participants
Started: Jan 22, 2024 · Completed: Sep 15, 2025
Locations (1)
Headquarters
ZZ, China
Map

Loading map...